Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy shows promise as first defense against advanced lung cancer

NCT ID NCT03003962

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 30 times

Summary

This study tests whether the immunotherapy drug durvalumab works better than standard chemotherapy as the first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. About 669 adults with stage IV lung cancer, who have not had prior chemotherapy, will receive either durvalumab or platinum-based chemo. The main goal is to see if durvalumab helps people live longer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CARCINOMA NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Anaheim, California, 92801, United States

  • Research Site

    Box Hill, 3128, Australia

  • Research Site

    Gosford, 2250, Australia

  • Research Site

    Kogarah, 2217, Australia

  • Research Site

    St Leonards, 2065, Australia

  • Research Site

    Beijing, 100032, China

  • Research Site

    Beijing, 100142, China

  • Research Site

    Beijing, 100853, China

  • Research Site

    Bengbu, 233004, China

  • Research Site

    Changchun, 130000, China

  • Research Site

    Changsha, 410013, China

  • Research Site

    Chengdu, 610041, China

  • Research Site

    Chongqing, 400030, China

  • Research Site

    Guangzhou, 510080, China

  • Research Site

    Guangzhou, 510095, China

  • Research Site

    Haikou, 570311, China

  • Research Site

    Hangzhou, 310003, China

  • Research Site

    Hangzhou, 310006, China

  • Research Site

    Hangzhou, 310009, China

  • Research Site

    Hangzhou, 310022, China

  • Research Site

    Jinan, 250031, China

  • Research Site

    Linhai, 317000, China

  • Research Site

    Nanchang, 330006, China

  • Research Site

    Nanjing, 210009, China

  • Research Site

    Ningbo, 315010, China

  • Research Site

    Shanghai, 200030, China

  • Research Site

    Shenyang, 110042, China

  • Research Site

    Shijiazhuang, 050020, China

  • Research Site

    Ürümqi, 830000, China

  • Research Site

    Ürümqi, 830054, China

  • Research Site

    Wanzhou, 404000, China

  • Research Site

    Wenzhou, CN-325000, China

  • Research Site

    Wuhan, 430010, China

  • Research Site

    Wuhan, 430022, China

  • Research Site

    Wuhan, 430030, China

  • Research Site

    Xi'an, 710038, China

  • Research Site

    Xi'an, 710061, China

  • Research Site

    Zhengzhou, 450008, China

  • Research Site

    Zhuhai, 519099, China

  • Research Site

    Budapest, 1083, Hungary

  • Research Site

    Budapest, 1121, Hungary

  • Research Site

    Budapest, 1122, Hungary

  • Research Site

    Deszk, 6772, Hungary

  • Research Site

    Farkasgyepü, 8582, Hungary

  • Research Site

    Gyöngyös - Mátraháza, 3200, Hungary

  • Research Site

    Székesfehérvár, 8000, Hungary

  • Research Site

    Törökbálint, 2045, Hungary

  • Research Site

    Almelo, 7600SZ, Netherlands

  • Research Site

    Bialystok, 15-027, Poland

  • Research Site

    Grudziądz, 86-300, Poland

  • Research Site

    Koszalin, 75-581, Poland

  • Research Site

    Lublin, 20-090, Poland

  • Research Site

    Mrozy, 05-320, Poland

  • Research Site

    Warsaw, 02-781, Poland

  • Research Site

    Wroclaw, 53-413, Poland

  • Research Site

    Arkhangelsk, 163045, Russia

  • Research Site

    Moscow, 115478, Russia

  • Research Site

    Novosibirsk, 630108, Russia

  • Research Site

    Omsk, 644013, Russia

  • Research Site

    Rostov-on-Don, 344037, Russia

  • Research Site

    Saint Petersburg, 194291, Russia

  • Research Site

    Saint Petersburg, 196603, Russia

  • Research Site

    Saint Petersburg, 197183, Russia

  • Research Site

    Saint Petersburg, 197342, Russia

  • Research Site

    Saint Petersburg, 197758, Russia

  • Research Site

    Volgograd, 400138, Russia

  • Research Site

    Changwon-si, 51353, South Korea

  • Research Site

    Cheongju-si, 28644, South Korea

  • Research Site

    Daegu, 42415, South Korea

  • Research Site

    Incheon, 21565, South Korea

  • Research Site

    Jinju, 660-702, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Suwon, 16499, South Korea

  • Research Site

    Taichung, 402, Taiwan

  • Research Site

    Taichung, 40705, Taiwan

  • Research Site

    Taipei, 112, Taiwan

  • Research Site

    Taipei, 235, Taiwan

  • Research Site

    Bangkok, 10330, Thailand

  • Research Site

    Bangkok, 10700, Thailand

  • Research Site

    Muang, 50200, Thailand

  • Research Site

    Songkhla, 90110, Thailand

  • Research Site

    Ankara, 06490, Turkey (Türkiye)

  • Research Site

    Istanbul, 34030, Turkey (Türkiye)

  • Research Site

    Istanbul, 34854, Turkey (Türkiye)

  • Research Site

    Malatya, 44100, Turkey (Türkiye)

  • Research Site

    Pamukkale, 20070, Turkey (Türkiye)

  • Research Site

    Can Tho, 900000, Vietnam

  • Research Site

    Hanoi, 100000, Vietnam

  • Research Site

    Hanoi, 10000, Vietnam

  • Research Site

    Ho Chi Minh City, 10000, Vietnam

  • Research Site

    Ho Chi Minh City, 700000, Vietnam

  • Research Site

    Ho Chi Minh City, 70000, Vietnam

Conditions

Explore the condition pages connected to this study.

NON SMALL CELL LUNG CARCINOMA NSCLC NON SMALL CELL LUNG CARCINOMA NSCLC